Sensei Biotherapeutics, Inc. has completed the Sensei Biotherapeutics acquisition of Faeth Therapeutics and announced a concurrent $200 million private placement. This strategic move expands Sensei’s oncology pipeline while strengthening its financial position to advance key clinical programs.
Through the Sensei Biotherapeutics acquisition of Faeth, the company adds Faeth’s lead asset, PIKTOR, to its portfolio. Faeth Therapeutics Inc. developed PIKTOR as a proprietary, investigational all-oral combination therapy targeting tumor metabolism and signaling. Specifically, PIKTOR combines serabelisib and sapanisertib to inhibit multiple nodes of the PI3K/AKT/mTOR pathway by targeting PI3K-alpha and dual mTORC1/2.
$200 Million Private Placement Strengthens Capital Position
In connection with the Sensei Biotherapeutics acquisition of Faeth, the company entered into a definitive agreement for a private placement of Series B non-voting convertible preferred stock. The financing is expected to generate approximately $200 million in gross proceeds before expenses.
The private placement included participation from leading institutional investors such as RA Capital Management and Vivo Capital, along with several other life sciences-focused funds. As a result, Sensei believes it is well capitalized to execute its near-term clinical strategy.
Advancing PIKTOR Through Key Clinical Milestones
The proceeds from the Sensei Biotherapeutics acquisition of Faeth and the private placement will primarily support the development of PIKTOR. The company plans to report topline data from an ongoing Phase 2 trial in second-line advanced endometrial cancer by the end of 2026. Additionally, it expects to initiate a Phase 1b trial in HR+/HER2- advanced breast cancer within the same timeframe.
Bob Holmen, Chairman of the Board of Directors at Sensei, emphasized that the clinical data and investor participation reinforce confidence in the program. Meanwhile, Anand Parikh, Co-founder of Faeth and newly appointed Chief Operating Officer and director at Sensei, highlighted PIKTOR’s dual-targeting approach as a potential solution to the efficacy and tolerability challenges seen with single-node PI3K inhibitors.
Overall, the Sensei Biotherapeutics acquisition of Faeth positions the company to accelerate development in endometrial and breast cancer while maintaining momentum in its ongoing Phase 1/2 trial of solnerstotug.
Read Also: ImmunityBio Advances Regulatory Plans with SFDA Under Saudi-USA Biotech Alliance
